LYSAKER, NORWAY - Pronova BioPharma ASA announced in a Tuesday press release that it has filed a Terminal Disclaimer in US Patent No. 5,656,667 ('667 Patent) with the US Patent and Trademark Office.
The '667 Patent is listed in the FDA's Orange Book with respect to Lovaza. A Terminal Disclaimer was filed by Pronova BioPharma to disclaim the terminal part of the statutory term under 35 U.S.C. § 154 of the '667 patent which would extend beyond the expiration date of the full statutory term of US Patent No. 5,502,077 ('077 Patent), also listed in the Orange Book with respect to Lovaza.
With patent term extension under 35 U.S.C. § 156, the '677 patent will now expire on April 10, 2017.
Pronova BioPharma is a global leader in the research, development and manufacture of marine-originated omega-3 derived pharmaceutical products.
From:AGIPNEWS
